Cardiff Oncology, Inc. (NASDAQ: CRDF) reported Q3 EPS of ($0.25), $0.02 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $165 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Cardiff Oncology, Inc. (CRDF) click here.